Abstract
About 10-20% of Familial Mediterranean Fever (FMF) patients do not achieve complete remission, due to colchicine resistance or sensitivity. Disease control in these patients is still an unmet challenge. Case reports and a small case control study, suggest a role for interleukin 1 beta blockage, particularly anakinra, in the management of this limitation of colchicines.
Highlights
About 10-20% of familial Mediterranean fever (FMF) patients do not achieve complete remission, due to colchicine resistance or sensitivity
To embark on a study, evaluating the efficacy and safety of anakinra in the treatment of colchicine refractory FMF
A favorable anakinra effect in the prevention of FMF attacks in colchicine failure, supported by ample case reports is expected to be confirmed by the present controlled double blinded study by mid 2015
Summary
About 10-20% of familial Mediterranean fever (FMF) patients do not achieve complete remission, due to colchicine resistance or sensitivity. P01-031 – Anakinra for colchicine resistant FMF I Ben-Zvi1*, OL Kukuy1, M Lidar1, O Feld1, O Perski1, S Kivity1, P Langevitz1, B Pistrom2, A Livneh1 From 7th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID) Lausanne, Switerland.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
